In brief: Eqitx, Stirling Products
Monday, 12 July, 2004
Two Perth-based biotechs have made key executive appointments.
Drug development company Eqitx (ASX:EQX) has former CSL and Amrad business development executive Joy Hewitt as its chief commercialisation officer.
At CSL, Hewitt was R&D and pharmaceuticals business development manager, where her responsibilities included commercialising CSL projects, evaluating and securing R&D opportunities, and in-licensing pharmaceutical products for domestic and NZ markets. Eqitx said Hewitt had also acted as a consultant to Australian research, biotech and medical organisations.
Animal growth promoter specialist Stirling Products (ASX:STI) has appointed Murray Ward, a stockbroker with 20 years' experience, as an executive director.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
